A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

吉利德科学宣布了一个重要的里程碑：美国FDA接受了lenacapavir （LEN）的新药申请（NDAs）， lenacapavir （LEN）是一种突破性的每年两次注射的HIV-1衣壳抑制剂，用于暴露前预防（PrEP）。

Lenacapavir是一种“first-in-class”长效HIV病毒衣壳抑制剂，可以干扰HIV病毒衣壳蛋白的组装和拆卸，在病毒生命周期的多个阶段发挥作用。它已经获得美国FDA授予的突破性疗法认定，用于HIV病毒感染暴露前预防。2024年，《科学 ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

近日，国内媒体报道称，“艾滋病疫苗”来那帕韦（Lenacapavir）即将上市，每年两针可预防HIV，年费用高达32.6万元。此说法迅速引发热议，但实际上，来那帕韦并非疫苗，而是一种长效HIV衣壳抑制剂，最初用于治疗多重耐药HIV感染者，同时作为长效PrEP（HIV暴露前预防）药物使用。

随着医学技术的进步，全世界对于艾滋病的认识与防治逐渐深入。如今，一种可能革新艾滋病预防策略的新药——来那帕韦（Lenacapavir）即将在中国上市，但其年费用高达30万元，这引发了广泛的关注与讨论。那么，这种药物究竟是什么，它如何帮助预防HIV，又为何价格如此昂贵呢？

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...